CRON
Price
$2.50
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
966.06M
60 days until earnings call
EBS
Price
$7.58
Change
-$0.05 (-0.66%)
Updated
Sep 5 closing price
Capitalization
404.4M
60 days until earnings call
Interact to see
Advertisement

CRON vs EBS

Header iconCRON vs EBS Comparison
Open Charts CRON vs EBSBanner chart's image
Cronos Group
Price$2.50
Change-$0.00 (-0.00%)
Volume$1.97M
Capitalization966.06M
Emergent Biosolutions
Price$7.58
Change-$0.05 (-0.66%)
Volume$830.96K
Capitalization404.4M
CRON vs EBS Comparison Chart in %
Loading...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRON vs. EBS commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a Hold and EBS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (CRON: $2.50 vs. EBS: $7.58)
Brand notoriety: CRON and EBS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRON: 73% vs. EBS: 69%
Market capitalization -- CRON: $966.06M vs. EBS: $404.4M
CRON [@Pharmaceuticals: Generic] is valued at $966.06M. EBS’s [@Pharmaceuticals: Generic] market capitalization is $404.4M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRON’s FA Score shows that 1 FA rating(s) are green whileEBS’s FA Score has 1 green FA rating(s).

  • CRON’s FA Score: 1 green, 4 red.
  • EBS’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than CRON.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRON’s TA Score shows that 3 TA indicator(s) are bullish while EBS’s TA Score has 7 bullish TA indicator(s).

  • CRON’s TA Score: 3 bullish, 6 bearish.
  • EBS’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, EBS is a better buy in the short-term than CRON.

Price Growth

CRON (@Pharmaceuticals: Generic) experienced а -3.85% price change this week, while EBS (@Pharmaceuticals: Generic) price change was -8.67% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

CRON is expected to report earnings on Nov 05, 2025.

EBS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRON($966M) has a higher market cap than EBS($404M). CRON has higher P/E ratio than EBS: CRON (50.00) vs EBS (2.89). CRON YTD gains are higher at: 23.762 vs. EBS (-20.711). EBS has higher annual earnings (EBITDA): 344M vs. CRON (-25.58M). CRON has more cash in the bank: 834M vs. EBS (267M). CRON has less debt than EBS: CRON (2.01M) vs EBS (668M). EBS has higher revenues than CRON: EBS (812M) vs CRON (130M).
CRONEBSCRON / EBS
Capitalization966M404M239%
EBITDA-25.58M344M-7%
Gain YTD23.762-20.711-115%
P/E Ratio50.002.891,728%
Revenue130M812M16%
Total Cash834M267M312%
Total Debt2.01M668M0%
FUNDAMENTALS RATINGS
CRON vs EBS: Fundamental Ratings
CRON
EBS
OUTLOOK RATING
1..100
1468
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9132
PRICE GROWTH RATING
1..100
4142
P/E GROWTH RATING
1..100
664
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (54) in the Biotechnology industry is in the same range as CRON (68) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to CRON’s over the last 12 months.

EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to CRON’s over the last 12 months.

EBS's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for CRON (91) in the Pharmaceuticals Other industry. This means that EBS’s stock grew somewhat faster than CRON’s over the last 12 months.

CRON's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as EBS (42) in the Biotechnology industry. This means that CRON’s stock grew similarly to EBS’s over the last 12 months.

CRON's P/E Growth Rating (6) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (64) in the Biotechnology industry. This means that CRON’s stock grew somewhat faster than EBS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRONEBS
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 10 days ago
71%
Bullish Trend 17 days ago
76%
Declines
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
73%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANOAX21.610.12
+0.56%
American Century Small Cap Growth A
ARABX14.77N/A
N/A
Aristotle Small Cap Eq A
SCCFF0.37N/A
N/A
Strategic Resources Inc.
MRGSX24.01-0.02
-0.08%
BlackRock Advantage Global R
TFOAX80.74-0.32
-0.39%
Touchstone Focused A

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been loosely correlated with TLRY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CRON jumps, then TLRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
N/A
TLRY - CRON
61%
Loosely correlated
+3.48%
OGI - CRON
58%
Loosely correlated
+2.48%
CGC - CRON
57%
Loosely correlated
+5.80%
ACB - CRON
55%
Loosely correlated
+1.66%
EBS - CRON
29%
Poorly correlated
-0.66%
More

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-0.66%
SIGA - EBS
43%
Loosely correlated
-0.82%
VTRS - EBS
42%
Loosely correlated
+1.65%
ELAN - EBS
39%
Loosely correlated
+5.50%
HKMPF - EBS
34%
Loosely correlated
N/A
PAHC - EBS
33%
Poorly correlated
+0.97%
More